Disease Progression on PROs in Patients With aNSCLC With PD-L1 ?50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1

Gumus, M.Kilickap, S.Sezer, A.Bondarenko, I.Ozguroglu, M.Gogishvili, M.He, X.2024-05-192024-05-1920231556-08641556-1380https://hdl.handle.net/20.500.12713/4867[Abstract Not Available]eninfo:eu-repo/semantics/closedAccessCemiplimabAdvancedNsclcPatient-Reported OutcomesDisease Progression on PROs in Patients With aNSCLC With PD-L1 ?50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1Conference Object1811S321S321WOS:001098831600537N/A